Climb Bio
CLYM
20 hedge funds and large institutions have $61M invested in Climb Bio in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 4 closing their positions.
28% more capital invested
Capital invested by funds: $47.8M → $61M (+$13.2M)
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
6.85% more ownership
Funds ownership: 55.73% → 62.58% (+6.9%)
9% less funds holding
Funds holding: 22 → 20 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$603K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$74.9K |
| 3 |
AI
Atom Investors
Austin,
Texas
|
+$25.4K |
| 4 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$21.1K |
| 5 |
BlackRock
New York
|
+$985 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$732K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$37K |
| 3 |
Morgan Stanley
New York
|
-$13.7K |
| 4 |
Millennium Management
New York
|
-$13K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$3.86K |
CLYM Hedge Fund Activity: Q4 2022 in Review
20 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Climb Bio (CLYM) for Q4 2022, worth a combined $61M — up 28% from $47.8M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CLYM and 2 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 7 added.
The largest buyer was Driehaus Capital Management, adding an estimated $603K. The largest seller was Woodline Partners, exiting entirely with an estimated $732K sold.
- 20 institutional investors held Climb Bio (CLYM) as of Q4 2022, down from 22 in Q3 2022.
- Funds reported $61M of Climb Bio stock for Q4 2022, up 28% quarter-over-quarter.
- 2 funds opened new Climb Bio positions in Q4 2022 and 4 closed out, a net change of -2 holders.
- The largest Climb Bio buyer in Q4 2022 was Driehaus Capital Management, an estimated $603K added.
- The largest Climb Bio seller in Q4 2022 was Woodline Partners, an estimated $732K sold.
Based on aggregated 13F filings for Q4 2022.